Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: A randomized open-label trial

• Published in: Progress in neuro-psychopharmacology & biological psychiatry Vol. 35; no. 8; pp. 1983 - 1989
• Main Authors: Nakajima, Shinichiro, Uchida, Hiroyuki, Suzuki, Takefumi, Watanabe, Koichiro, Hirano, Jinichi, Yagihashi, Tatsuhiko, Takeuchi, Hiroyoshi, Abe, Takayuki, Kashima, Haruo, Mimura, Masaru
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier Inc 01.12.2011; Elsevier
• Subjects: Adult; Adult and adolescent clinical studies; Aged; Antidepressant; Antidepressive Agents - therapeutic use; Biological and medical sciences; Citalopram - therapeutic use; Depression; Depressive Disorder, Major - drug therapy; Drug Substitution; Female; Humans; Major depressive disorder; Male; Medical sciences; Middle Aged; Mood disorders; Neuropharmacology; Onset; Paroxetine - therapeutic use; Pharmacology. Drug treatments; Predictor; Prospective Studies; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease); Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Psychopharmacology; Sertraline - therapeutic use; Switching; Time Factors; Treatment Outcome; PAR; Antidepressant; SER; DSM-IV; SSRIs; Predictor; MADRS; MDD; Major depressive disorder; Switching; Onset; QEEG; CGI-S; CYP; MMRM; Mood disorder; Psychotropic; Acute; Depression; Drug conversion; Randomization; Treatment; Antidepressant agent; Early; Predictive factor

Treatment guidelines for major depressive disorder (MDD) recommend a continuous use of antidepressants for several weeks, while recent meta-analyses indicate that antidepressant efficacy starts to appear within 2weeks and early treatment nonresponse is a predictor of subsequent nonresponse. We prosp...